Navigation Links
BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman

SAN DIEGO, Oct. 20 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary neural stem cell platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced the appointment of Drs. Edward Scolnick from the Broad Institute of MIT and Harvard and David Holtzman of Washington University School of Medicine to its scientific advisory board. The appointees join BrainCells' advisory boards comprised of world-class scientists of neurogenesis and CNS disease. Existing board members represent The Salk Institute, Columbia University, Stanford University, Cedars-Sinai Medical Center and Massachusetts General Hospital.

"Ed and David are two highly esteemed and accomplished neuroscientists; a great honor for the company and a validation of our research in neurogenesis," said Jim Schoeneck, chief executive officer of BrainCells Inc. "Their backgrounds in research and drug development will be invaluable as we prioritize clinical applications for our assets. In the past five years, we've screened more than 1,000 compounds against 150 novel and known mechanisms, moved neurogenic compounds into Phase 2 clinical trials and identified several preclinical candidates."

Dr. Edward Scolnick is an internationally recognized thought leader in neuroscience research. He currently serves as director of the Psychiatric Disease Program and the Stanley Center for Psychiatric Research at the Broad Institute, focused on identifying risk genes for bipolar disorder and schizophrenia. Prior to joining the Broad Institute, Dr. Scolnick spent more than 20 years with Merck in various positions including president of Merck Research Laboratories. He has also worked at the National Cancer Institute and National Heart Association. Dr. Scolnick is a member of National Academy of Sciences, the American Academy of Arts and Sciences and the Institute of Medicine. He served on the board of Directors at Merck & Co., Inc. from 1997 to 2002 and is a current board member for Millipore Corporation and Alnylam Pharmaceuticals. Dr. Scolnick holds an A.B. from Harvard College and an M.D. from Harvard University Medical School.

Dr. David Holtzman is the Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer's Disease Research Center, and a member of the Hope Center for Neurological Disorders at Washington University School of Medicine. His research focuses on understanding basic mechanisms underlying acute and chronic cell dysfunction in the CNS, particularly how mechanisms may relate to Alzheimer's disease and injury to the developing brain. Prior to Washington University, Dr. Holtzman established the Memory and Cognitive Disorders Clinic at UCSF. Over the course of his career Dr. Holtzman has been recognized with the Paul Beeson Physician Faculty Scholar Award in Aging Research, the Potamkin Prize from the American Academy of Neurology for research on Alzheimer's, election to the American Society for Clinical Investigation, recipient of a MERIT award from the NIA, the MetLife award on Alzheimer's disease and election to the Institute of Medicine of the National Academy of Sciences. Dr. Holtzman holds a B.S. and M.D. from Northwestern University.

About BrainCells Inc.

BrainCells Inc. (BCI) is a drug discovery and development company leading the scientific research of neurogenesis by applying its robust and proprietary platform technology to identify novel pathways for new therapeutics to treat various central nervous system (CNS) diseases. Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. With its predictive screening platform, BCI can direct the selection and development of neurogenic compounds, increasing the opportunity for successful clinical trials in a variety of indications. For more information, visit

    Media Contact:
    Kim Richards
    Porter Novelli Life Sciences

SOURCE BrainCells Inc.

SOURCE BrainCells Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
2. Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
3. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
4. Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
7. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
8. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
9. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
10. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
11. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
Post Your Comments:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
Breaking Medicine News(10 mins):